Cargando…
Fresh from the biotech pipeline: fewer approvals, but biologics gain share
2022 saw a 25% drop in new drug approvals and a less predictable regulator.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group US
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838261/ https://www.ncbi.nlm.nih.gov/pubmed/36624153 http://dx.doi.org/10.1038/s41587-022-01630-6 |